All of the following are third generation antipsychotics except,

A. Lurasidone (Latuda) is a second-generation (atypical) antipsychotic, not a third-generation antipsychotic. It primarily blocks dopamine (D2) and serotonin (5-HT2A) receptors and is used to treat schizophrenia and bipolar depression. B. Cariprazine (Vraylar) is a third-generation antipsychotic, functioning as a partial dopamine (D2/D3) and serotonin (5-HT1A) receptor agonist. It is used for schizophrenia, bipolar disorder, and major depressive disorder (MDD) adjunctive treatment. C. Haloperidol (Haldol) is a first-generation (typical) antipsychotic, not a third-generation antipsychotic. It works by strongly blocking D2 receptors, leading to a high risk of extrapyramidal symptoms (EPS) but lower metabolic side effects compared to atypical antipsychotics. D. Aripiprazole (Abilify) is a third-generation antipsychotic, known for its partial dopamine (D2) agonist properties. It has a lower risk of EPS and metabolic side effects compared to second-generation antipsychotics and is used for schizophrenia, bipolar disorder, and adjunctive treatment in depression.